^
    24d
    Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma (clinicaltrials.gov)
    P2, N=41, Recruiting, St. Jude Children's Research Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV • mesna • B7-H3 CAR-T
    1m
    Dual-modality imaging enables longitudinal biodistribution profiling of intracerebroventricular CAR-T therapy in orthotopic glioma. (PubMed, Cancer Immunol Immunother)
    Here, we report a dual-modality cell labeling and tracking strategy based on indocyanine green-conjugated iron nanoparticles (ICG-NPs) for in vivo assessment of B7-H3-targeting CAR-T cell (TX103) biodistribution using second near-infrared window (NIR-II) fluorescence imaging and magnetic resonance imaging (MRI)...Furthermore, organ-level NIR-II exposure showed a positive association with CD3⁺ T-cell density across organs (R2 = 0.552, p < 0.001), supported by multi-organ pathological validation. Collectively, we establish a biocompatible dual-modality workflow that links intracranial anatomical localization with longitudinal whole-body biodistribution readouts for preclinical CAR-T tracking in solid tumor models.
    Journal • IO biomarker
    |
    CXCR3 (C-X-C Motif Chemokine Receptor 3)
    1m
    STRIvE-02: B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (clinicaltrials.gov)
    P1, N=68, Active, not recruiting, Seattle Children's Hospital | Trial primary completion date: Dec 2025 --> Dec 2040
    Trial primary completion date
    |
    Keytruda (pembrolizumab) • SCRI-CARB7H3(s) • SCRI-CARB7H3(s)x19
    2ms
    Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma (clinicaltrials.gov)
    P2, N=41, Not yet recruiting, St. Jude Children's Research Hospital | Initiation date: Feb 2026 --> Jun 2026
    Trial initiation date
    |
    cyclophosphamide • fludarabine IV • mesna • B7-H3 CAR-T
    2ms
    B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) (clinicaltrials.gov)
    P1, N=48, Recruiting, St. Jude Children's Research Hospital | N=32 --> 48 | Trial completion date: Mar 2027 --> Mar 2028 | Trial primary completion date: Mar 2026 --> Mar 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CD276 (CD276 Molecule)
    |
    cyclophosphamide • fludarabine IV • mesna • B7-H3 CAR-T
    2ms
    Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells (clinicaltrials.gov)
    P1, N=27, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Mar 2026 --> Apr 2036 | Trial primary completion date: Mar 2026 --> Apr 2036
    Trial completion date • Trial primary completion date • Platinum resistant
    |
    cyclophosphamide • fludarabine IV • CAR.B7-H3 T
    2ms
    BrainChild-03: Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors (clinicaltrials.gov)
    P1, N=90, Recruiting, Seattle Children's Hospital | Trial completion date: May 2041 --> May 2042 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    SCRI-CARB7H3(s)
    2ms
    RASA2 deletion rescues immune synapse dysfunction, enhancing CAR T cell efficacy against DMGs. (PubMed, J Immunother Cancer)
    Our study highlights the importance of understanding tumor-specific factors that limit CAR T-cell response and using this information to design superior next-generation CAR T-cells. Specifically, we identify cytoskeleton remodeling and T cell motility as therapeutically actionable targets for future engineering approaches.
    Journal
    |
    CD276 (CD276 Molecule)
    |
    B7-H3 CAR-T
    3ms
    Autologous CAR-T Cells Targeting B7-H3 in PDAC (clinicaltrials.gov)
    P1, N=27, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Jun 2028 --> Apr 2030 | Trial primary completion date: Jun 2026 --> Apr 2028
    Trial completion date • Trial primary completion date • IO biomarker
    |
    CAR.B7-H3 T
    3ms
    Tumor inflammation-associated neurotoxicity in children with diffuse intrinsic pontine glioma receiving B7-H3-targeting CAR T cells on BrainChild-03. (PubMed, Neurooncol Pract)
    This study retrospectively applies TIAN criteria to patients with DIPG/pontine DMG treated with intraventricular B7-H3 CAR T cells in the BrainChild-03 (BC-03) trial (NCT04185038)...TIAN was common within this cohort but mostly low-grade and transient. Refining its classification and understanding its clinical impact will aid safety assessments and trial comparisons for CNS-directed CAR T therapies.
    Journal
    |
    CD276 (CD276 Molecule)
    |
    B7-H3 CAR-T
    3ms
    Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=9, Recruiting, Chulalongkorn University | Trial primary completion date: Dec 2026 --> Dec 2027 | Trial completion date: Dec 2027 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    CD276 (CD276 Molecule) • IL7R (Interleukin 7 Receptor)
    4ms
    Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma (clinicaltrials.gov)
    P2, N=41, Not yet recruiting, St. Jude Children's Research Hospital
    New P2 trial
    |
    cyclophosphamide • fludarabine IV • mesna • B7-H3 CAR-T